

Long-term outcomes for heart attack patients treated with a naturally-dissolving blood vessel support

Submission date 04/06/2019	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 07/06/2019	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 20/01/2022	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

A bioresorbable scaffold (BRS) can hypothetically decrease the risk of an adverse cardiac event in the long-term perspective. The BRS is a device which is inserted into a blood vessel in order to expand the vessel to prevent or alleviate a blockage, manufactured from a material that may dissolve or be absorbed in the body. The of the study is to assess the long-term outcomes of using a BRS for the urgent treatment of coronary artery block.

Who can participate?

Patients undergoing surgery for STEMI type heart attack.

What does the study involve?

Patients undergoing urgent surgery for a STEMI type heart attack will be treated using the BRS and followed up over 5-years during their regular appointments.

What are the possible benefits and risks of participating?

An improved long-term outcome with normal vessel anatomy (no vessel metallic cage as the device is resorbed over time).

Higher risk of scaffold late thrombosis.

Where is the study run from?

1. University Hospital Kralovske Vinohrady third medical faculty, Charles University, Czechia
2. Military hospital Prague, Czechia

When is the study starting and how long is it expected to run for?

December 2012 to December 2020

Who is funding the study?

Univerzita Karlova v Praze (Charles University, Prague), Czechia

Who is the main contact?

Dr Petr Tousek,
petr.tousek@fnkv.cz

Contact information

Type(s)

Scientific

Contact name

Dr Petr Tousek

ORCID ID

<https://orcid.org/0000-0002-2598-3635>

Contact details

University Hospital Vinohrady
Srobarova 50
Prague
Czech Republic
10034
0042 067162701
petr.tousek@fnkv.cz

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

Nil known

Study information

Scientific Title

Bioresorbable scaffold implantation in STEMI patients

Acronym

PRAGUE-19

Study objectives

Good longterm clinical outcome after bioresorbable scaffold (BRS) implantation, complete scaffold resorbtion at 5 year with stable lumen patency

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Approved 09/01/2013, Local and multicenter ethical committee of the University Hospital Kralovske Vinohrady (Srobatrova 50, Prague 10, eticka.komise@fnkv.cz, +420267162272), ref: EK-VP/02/2013
2. Amendment approved 03/10/2018, ref: EK-VP/02/4/2013

Study design

Prospective two-centre open-label registry study

Primary study design

Observational

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Acute myocardial infarction with ST segment elevation

Interventions

Use of bioresorbable scaffold (AbsorbTM BRS) during primary coronary intervention. Patients enrolled in this study were treated during primary percutaneous coronary intervention (PCI) with the bioresorbable scaffold implantation (in some of the patients, optical coherence tomography (OCT) was performed just after BRS was implanted - if clinically possible). Patients are followed by clinical and phone controls during 5 years. First 25 eligible patients that agreed with the control invasive imaging underwent 5 year coronary angiography and OCT.

Intervention Type

Device

Phase

Phase IV

Primary outcome(s)

At 5 years:

1. Death using patient records
2. MI using patient records
3. Target vessel revascularization as recorded in records by a specialist

Key secondary outcome(s)

Vessel invasive assessment using QCA and optical coherence tomography at baseline and 5 years.

Completion date

15/12/2020

Eligibility

Key inclusion criteria

1. STEMI patients
2. Sign informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

117

Key exclusion criteria

1. Severe calcification
2. Do not meet specified vessel size
3. Length of the lesion more than 28mm
4. Indication for anticoagulation, cardiogenic shock

Date of first enrolment

15/12/2012

Date of final enrolment

15/12/2015

Locations**Countries of recruitment**

Czech Republic

Study participating centre

University Hospital Kralovske Vinohrady third medical faculty, Charles university

Srobarova 50

Prague

Czech Republic

10034

Study participating centre

Military hospital Prague

U Vojenské nemocnice 1200

Prague

Czech Republic
16902

Sponsor information

Organisation

Charles University, University Research programme UNCE 02 and PROGRES Q38

ROR

<https://ror.org/024d6js02>

Funder(s)

Funder type

University/education

Funder Name

Univerzita Karlova v Praze

Alternative Name(s)

Charles University, Charles University in Prague, Univerzita Karlova, Karls-Universität zu Prag, UK

Funding Body Type

Government organisation

Funding Body Subtype

Universities (academic only)

Location

Czech Republic

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to ethical restrictions on data sharing.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
-------------	---------	--------------	------------	----------------	-----------------

Results article		30/01/2020	03/02/2020	Yes	No
Other publications	interim analysis	17/05/2016	05/06/2019	Yes	No
Other publications	pilot study	01/03/2014	05/06/2019	Yes	No